AMERISAFE Heads Into Q2 Print With Shorts Retreating
Produced automatically from ORTEX data and published under the ORTEX News editorial standards set by Peter Hillerberg, Editor, ORTEX News. How we publish
AMSF reports Q2 results today with one clear signal: short sellers have been pulling back even as the stock drifted lower.
Short interest has fallen roughly 7% over the past week to 4.1% of the free float — a meaningful retreat given that the position had ballooned 46% over the prior month. The borrow market reinforces the picture. Availability is exceptionally loose at over 5,000% of short interest, meaning there are roughly 50 shares available to lend for every one currently borrowed. Cost to borrow has crept up about 48% on the week but remains negligible in absolute terms at 0.66%. That combination — shorts trimming into the print, ample borrow supply, and cheap financing — points to a lending market under no meaningful pressure. Options tell the same story: the put/call ratio of 0.40 is slightly below its 20-day average and nearly flat on a z-score basis, suggesting options traders are not reaching for downside protection ahead of the release.
The bull and bear debate on AMERISAFE turns on a familiar tension for workers' compensation specialists. Bulls point to 5% gross written premium growth matching estimates, with voluntary premiums accelerating at 7.1%, alongside a 12.7-point benefit from prior-period reserve development that bolstered last quarter's results. Bears counter with a book value that has grown only marginally — at $13.69 per share as of the most recent disclosure — and flag the structural risk of adverse reserve development in a niche that concentrates exposure in hazardous-occupation workers. Analyst coverage has drifted cautious over the past year, with both Truist Securities and Citizens trimming price targets across multiple quarters; the most recent moves, reported in late April, brought the Truist target to $34 and the Citizens target to $45. The mean consensus target of around $37 sits only modestly above the current price of $33.98, leaving limited implied upside and suggesting the Street sees fair value near current levels rather than a compelling re-rating story.
The peer backdrop adds a wrinkle. ERIE dropped 4.1% on the day and nearly 9.5% on the week — a notable underperformer among the correlated group — while HIG and SIGI both gained on the week, reflecting the mixed signals across the property and casualty space heading into the earnings season. AMSF's own one-month gain of 8.5% to $33.98 has outpaced most peers, which raises the question of whether the recent rally has already priced in an in-line print. The two most recent AMSF earnings reactions offer a cautionary note on that front: the April 2026 print produced a single-day drop of 6.2% and a five-day loss of 7.5%, while the prior quarter saw a more modest 1.1% one-day decline extending to a 2.9% five-day loss.
Today's print is therefore less a test of whether AMSF can grow premiums and more a test of whether the reserve development story holds — and whether an 8.5% monthly rally in a stock trading near the low end of analyst targets can survive contact with the numbers.
Stocks in this article
See the live data behind this article on ORTEX.
Open AMSF on ORTEX →How this article was generated
- Generated
- 22 Jul 2026, 04:12
- Data as of
- 22 Jul 2026, 04:00
- Prompt version
- v1.0
- Data sources
- Short interestCost to borrowUtilizationOptions flowEarningsInstitutional positioningORTEX Alpha signalsRecent ORTEX notes
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.